Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Elaine Lam and Thomas Flaig.

 
Connection Strength
 
 
 
3.417
 
  1. Lam ET, Flaig TW. Upfront Chemotherapy for Metastatic Prostate Cancer. Oncology (Williston Park). 2015 12; 29(12):956-62.
    View in: PubMed
    Score: 0.777
  2. Lam ET, Flaig TW. Prostate cancer: celecoxib trampled in the STAMPEDE trial. Nat Rev Urol. 2012 May 29; 9(7):358-60.
    View in: PubMed
    Score: 0.609
  3. Lam ET, La Rosa FG, Suby-Long TD, Kondo KL, Wilson S, Glodé LM, Flaig TW. A rare case of metastatic renal epithelioid angiomyolipoma. Oncology (Williston Park). 2011 Aug; 25(9):832-8.
    View in: PubMed
    Score: 0.575
  4. Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 12; 17(4):1103-1108.
    View in: PubMed
    Score: 0.237
  5. Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 2018; 7:307.
    View in: PubMed
    Score: 0.227
  6. Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol. 2017 03 01; 28(3):668.
    View in: PubMed
    Score: 0.212
  7. Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. Cancer Med. 2016 12; 5(12):3386-3393.
    View in: PubMed
    Score: 0.207
  8. Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep; 37(7):360-5.
    View in: PubMed
    Score: 0.178
  9. Lam ET, Kessler ER, Flaig TW, La Rosa FG. Collision renal cell papillary and medullary carcinoma in a 66-year-old man. Oncology (Williston Park). 2013 Sep; 27(9):893, 896, 898.
    View in: PubMed
    Score: 0.166
  10. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 06; 35(6):438-446.
    View in: PubMed
    Score: 0.053
  11. Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015 Oct 28; 10:218.
    View in: PubMed
    Score: 0.048
  12. Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol. 2015 Nov-Dec; 5(6):e589-e596.
    View in: PubMed
    Score: 0.047
  13. Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Drugs Today (Barc). 2013 May; 49(5):303-15.
    View in: PubMed
    Score: 0.041
  14. Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct; 48(10):633-44.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2019 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)